The Biopharma Strategic Adaptation Index 2026: Navigating the Velocity of Innovation

The Imperative of Live Adaptation in Biopharma’s New Era

TheThe biopharmaceutical sector stands at an inflection point, navigating a confluence of rapid technological advancements, evolving regulatory landscapes, and unprecedented market volatility. The traditional, slow-moving R&D pipelines and annual strategic cycles are no longer sufficient to maintain competitive advantage. In this era, strategic adaptation is not merely an option but a core competency, driven by continuous intelligence and agile execution. At enablegrowth, we believe that strategy must become a live, dynamic operating system, constantly calibrating against real-time market signals. This report, the Biopharma Strategic Adaptation Index 2026, provides a data-driven examination of how leading companies are responding to this velocity of change, highlighting key trends and offering insights for architecting truly adaptive strategies.

The Velocity of Change: Macro Trends Impacting Biopharma in 2026

The biopharma landscape in 2026 is characterized by several high-velocity trends that demand immediate and intelligent strategic responses. These include a paradoxical R&D environment, the pervasive integration of AI, a resilient M&A market, and the transformative impact of specific therapeutic areas like GLP-1 drugs.

R&D Investment & Productivity Paradox

Despite significant investment, R&D productivity remains a persistent challenge for the biopharma industry. Collective R&D expenditure by large pharmaceutical corporations increased to $190 billion in 2024, up from $163 billion in 2023, exceeding 25% of sales for the first time. However, this surge in spending does not uniformly translate into a proportional increase in successful outcomes. The average cost to develop a drug from discovery to launch grew to $2.67 billion in 2025, up from $2.23 billion the year before. While Deloitte's 16th annual 'Measuring the Return from Pharmaceutical Innovation' report indicated that the projected internal rate of return (IRR) on late-stage pipeline assets rose for the third consecutive year, hitting 7.0% in 2025 (up from 5.9% in 2024), a significant portion of this growth was attributed primarily to GLP-1/GIP drugs, which accounted for an estimated 38% of all projected commercial inflows from the 2025 late-stage pipeline. Without these, the IRR drops to 2.9%. This highlights a growing concentration of R&D value in a few high-impact areas, underscoring the need for more diversified, yet targeted, innovation strategies.

Clinical trial efficiency, a critical component of R&D productivity, saw stabilization in 2024 with trial starts returning to pre-pandemic levels (5,318 in 2024, comparable to 5,316 in 2019). Improvements in Phase III success rates contributed to an increase in overall clinical development productivity, with composite success rates from Phase I to approval rising from 6% in 2023 to 7% in 2024. However, median enrollment times for trials, particularly in oncology, continue to exceed 25 months. Organizations must develop real-time visibility into their R&D pipelines, utilizing data-driven insights to optimize resource allocation and accelerate development cycles, as advocated in our piece on Live Strategy Stacks: Reimagining Biotech & Pharma Agility.

The AI Imperative: Reshaping Discovery to Clinic

Artificial Intelligence (AI) and Machine Learning (ML) are no longer futuristic concepts but integral components of modern biopharma strategy. The global AI drug discovery market, valued between $1 billion to $1.7 billion in 2023, is projected to reach $9 billion or more by the end of the decade. The field is witnessing robust growth, with clinical trial AI leading publication volume, representing 72% of projected 2024 papers. AI in drug discovery could reduce development timelines by two years. Companies are pouring resources into AI R&D and analytics, with 93% of technology executives at life sciences companies expecting to increase investments in data, digital, and AI in 2025. More than 85% of biopharma executives surveyed planned to invest in data, AI, and digital tools by 2025. This rapid adoption, however, is not without its challenges; a 2025 Deloitte report concedes that AI’s promise to significantly reduce development time and costs “has not yet been realized at scale, largely due to a pilot-driven, function-by-function approach”. This underscores the importance of a holistic, enterprise-wide AI strategy, rather than siloed initiatives. The transformative potential of AI is further explored in our article on AI-Native Pharma: Turning Novartis, Lilly and Pfizer into Live Strategy Engines.

M&A as a Strategic Adaptation Lever

M&A activity in the biopharma sector remains a crucial strategic tool for portfolio optimization and innovation sourcing, especially in the face of patent cliffs impacting over $300 billion in sales between 2026 and 2030. Biopharma M&A volumes are expected to remain resilient, driven by the need to secure external innovation and offset patent expirations. The 'string of pearls' strategy, involving acquisitions of early- to mid-stage innovation, continues to be a dominant theme, with most activity in the $1 billion to $10 billion range. Oncology, immunology, and rare diseases are the primary focus areas for these deals.

In 2025, overall dealmaking remained disciplined, with a shift towards targeted acquisitions rather than broad, transformational megamergers. This momentum accelerated into early 2026, with Q1 deal value accounting for 36% ($36 billion) of the total 2025 deal value of $99.7 billion, and an average deal size of approximately $2.7 billion. This indicates a move toward larger, higher-conviction transactions. Notably, oncology led M&A by deal value in 2025 ($16.8 billion in deals over $1 billion), with neurology as a close secondary driver ($14.4 billion).

Market Dynamics: The GLP-1 Phenomenon

The GLP-1 (Glucagon-Like Peptide-1) drug market is undergoing explosive growth, fundamentally reshaping investment priorities and competitive dynamics. The global GLP-1 drugs market size, valued at $52.95 billion in 2025, is forecasted to reach $132.79 billion by 2035, growing at a CAGR of 9.63% from 2026 to 2035. Morgan Stanley projects the global incretin market (including GLP-1s) could reach $190 billion by 2035, exceeding previous estimates by $40 billion. The U.S. market alone is expected to reach $130.6 billion by 2033, growing at a CAGR of 12% from 2026 to 2033. This growth is driven by expanding therapeutic applications beyond type 2 diabetes to include obesity/weight management, cardiovascular risk reduction, and potentially neurodegenerative diseases. The introduction of oral GLP-1 treatments and expanded Medicare coverage in the U.S. are expected to significantly boost adoption. This unprecedented market expansion has led to a major reshuffling of R&D and commercial strategies across the industry.

Key Findings from The Biopharma Strategic Adaptation Index 2026

Our analysis reveals critical shifts in the biopharma sector's adaptive capacity in 2026:

• AI Integration is Accelerating, but Scalability Remains a Bottleneck: While investment in AI for drug discovery and development is robust (global market to exceed $9B by decade-end), widespread, systemic impact on R&D costs and timelines is still in its early stages due to fragmented approaches and data quality challenges. Companies that successfully implement modular, data-first AI strategies will gain a significant competitive edge.
• M&A Focus Shifts to Targeted Innovation: The era of mega-mergers is ceding to a 'string of pearls' strategy, with deal sizes predominantly in the $1-10 billion range. These acquisitions are laser-focused on plugging pipeline gaps in high-growth therapeutic areas like oncology, immunology, rare diseases, and increasingly, metabolic health, demonstrating a more disciplined approach to external innovation sourcing.
• GLP-1 Dominance Reshapes R&D Priorities: The explosive growth of the GLP-1 market, projected to reach $190 billion by 2035, has disproportionately influenced R&D returns, representing 38% of projected commercial inflows from late-stage pipelines in 2025. This creates both immense opportunity and a strategic risk of over-reliance, necessitating diversified portfolio management and sustained investment in other novel modalities.
• Digital Transformation is Uneven but Critical: Despite recognition of digital transformation's importance (82% of biopharma companies started their supply chain digitalization journey less than five years ago), progress remains slow and uneven. Leaders are differentiating themselves through operational efficiency, technology adoption, and workforce development, highlighting a growing digital maturity gap across the industry.
• Strategic Agility Demands Real-Time Telemetry: The dynamic nature of market shifts, technological breakthroughs, and regulatory changes necessitates a departure from static strategic planning. Organizations that adopt real-time market pulse monitoring and continuous strategic recalibration, mirroring the principles of a "live operating system," are best positioned for sustained growth.

Deep Dive: Strategic Adaptation Across Industry Leaders

Examining the strategic maneuvers of AstraZeneca, Moderna, and Eli Lilly provides tangible examples of adaptive strategies in action.

AstraZeneca’s Dynamic Portfolio Evolution

AstraZeneca has consistently demonstrated a strategy of sustained R&D investment coupled with targeted acquisitions to build a diversified, innovation-driven portfolio. In 2025, AstraZeneca continued to grow its R&D spending, with a 5% increase, albeit more modest than previous years, maintaining its position among the top R&D spenders globally and dedicating approximately a quarter of its total revenue to R&D. The company's focus on oncology, rare diseases, and cardiovascular-renal-metabolic (CVRM) diseases reflects a disciplined approach to therapeutic areas with high unmet needs and significant market potential. Their strategic pivots often involve acquiring clinical-stage assets or platforms that complement existing strengths, rather than foundational research, enabling faster market entry and pipeline expansion. This "string of pearls" approach is evident in the broader industry trend toward mid-sized deals. AstraZeneca's ability to integrate acquired assets and accelerate their development through optimized clinical trial processes highlights a mature strategic adaptation capability.

Moderna’s mRNA Platform Expansion & AI-Driven R&D

Moderna exemplifies a platform-centric strategy, leveraging its foundational mRNA technology across an expanding range of therapeutic areas. Beyond its success in infectious disease vaccines, Moderna is aggressively diversifying its pipeline into oncology, rare diseases, and autoimmune disorders. The company expects to double the number of programs by 2025 and launch up to 15 products in 5 years across cancer, rare disease, and infectious disease spaces, with up to 4 of those launches by 2025. Moderna plans to invest approximately $25 billion in R&D from 2024 through 2028.

A critical component of Moderna's adaptive strategy is its heavy investment in AI and digital tools to accelerate drug design, development, and production. The company recently unveiled 'Lucy,' an internal machine learning platform designed to run closed-loop experimental cycles, accelerating drug discovery across its pipeline. Furthermore, Moderna is enhancing its global manufacturing network, with three new facilities in the UK, Australia, and Canada coming fully online in 2025 to bolster pandemic readiness and efficient production. This integrated approach—combining platform innovation, aggressive pipeline expansion, and AI-driven operational excellence—positions Moderna as a highly adaptive disruptor.

Eli Lilly’s Market Leadership in Metabolic Health

Eli Lilly stands out for its strategic foresight and aggressive execution in the metabolic health sector, particularly with its GLP-1 class drugs. The company has established itself as a clear leader in the obesity market, capturing significant investor attention and enthusiasm. Lilly’s GLP-1 agonists, such as Mounjaro and Zepbound, are key drivers of the market's explosive growth. This strategic focus has been instrumental in reshaping their R&D portfolio and commercial strategy.

Lilly's acquisitions, like the $2.5 billion purchase of Scorpion Therapeutics' PI3Kα inhibitor program STX-478 in precision oncology in 2025, demonstrate a broader strategic vision that balances current market dominance with future innovation in other high-value areas. Their ability to rapidly scale manufacturing and navigate regulatory pathways for these blockbuster drugs showcases a high degree of strategic velocity and operational agility. Eli Lilly's success underscores the importance of identifying and aggressively pursuing emergent market opportunities while simultaneously nurturing a diverse pipeline.

The enablegrowth Perspective: Architecting Live Strategic Adaptation

The trends and case studies presented in this Index underscore a fundamental truth: static, periodic strategic planning is an anachronism. The speed and complexity of modern biopharma demand a 'live' strategy—an Intelligence-Augmented (IA) operating system that continuously adapts. At enablegrowth, our Strategy OS is built on principles that directly address these challenges:

1. Real-Time Telemetry: Moving beyond annual reviews, our system provides a continuous "Market Pulse," feeding real-time market signals directly into your strategic models. This ensures your organization is always calibrated to the latest R&D breakthroughs, M&A opportunities, and market shifts, rather than reacting belatedly to stale data.
2. Perspective-Pivot Engine (PPE): Understanding your strategic stance—whether as an Incumbent, Observer, or Disruptor—is critical. Our PPE helps biopharma leaders dynamically assess their competitive leverage and adjust their narrative and resource allocation accordingly. For instance, in a rapidly evolving market like GLP-1s, an "Incumbent" like Eli Lilly needs to protect its lead while an "Observer" might identify a niche, and a "Disruptor" could focus on novel delivery mechanisms or combination therapies.
3. Modular Strategic Frameworking: The monolithic annual plan is replaced by decoupled, adaptable strategic components. This allows for rapid iteration on R&D portfolio optimization, AI integration roadmaps, or M&A target identification without destabilizing the entire organizational strategy. This modularity reduces strategic drag and accelerates execution.

The financial cost of slow execution in the biopharma sector, particularly with drug development cycles stretching for years and billions of dollars, can be catastrophic. Each month of delay can mean hundreds of millions in lost revenue. Our approach emphasizes transforming strategy into actionable directives, linking justified decisions to accountable execution. If your current strategic processes are causing delays and draining resources, calculating your organizational's Strategy Drag can reveal the hidden costs.

In an industry where innovation is the lifeblood, and the pace of change is relentless, the ability to adapt in real-time is the ultimate competitive advantage. This requires robust market intelligence, the augmentation of human strategists with AI, and a modular framework that allows for continuous recalibration. It's about moving from planning for the future to living the strategy in the present. Effective strategic planning is no longer a separate function but an embedded, continuous process that determines survival and growth, as outlined in our Ultimate Strategic Planning Guide.

Future-Proof Your Biopharma Strategy: Act Now

The Biopharma Strategic Adaptation Index 2026 clearly demonstrates that the leaders of tomorrow are those building intelligence-augmented, real-time strategic capabilities today. The confluence of AI, dynamic M&A landscapes, and hyper-growth therapeutic areas demands a strategic operating system that moves at the speed of the market. Don't let your organization be sidelined by strategic inertia. Translate insight into immediate action and transform your potential into predictable growth.

Join the waitlist for Strategy OS →